Cantab set to buy anti-smoking drug
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.CANTAB PHARMACEUTICALS, the drug development company, will today offer hope to millions of smokers and drug addicts with the $9m (pounds 5.5m) purchase of two vaccines against nicotine and cocaine.
Cantab is set to reveal that it is buying the two drugs, currently in clinical trials in the US, from the American biotechnology firm ImmunoLogic.
The acquisition will be funded through the issue of around two million Cantab shares at a slight premium to Friday's closing share price of 202.5p, leaving ImmunoLogic with nearly 6 per cent of the UK group.
The deal will give Cantab, which has a number of other vaccines in its pipeline, access to two potentially huge markets. Recent research shows that there are 50 million daily smokers in the US alone, 17 million of whom attempt to quit smoking each year. More than $350m is spent annually on prescription and over-the-counter drugs by people trying to give up nicotine in the US.
The cocaine vaccine will target the millions of heavy users of the drug. In the US, more than two million people use cocaine on a regular basis and 900,000 of them seek treatment each year.
The vaccines are designed to generate antibodies that neutralise the effects of the two substances. Experts believe they could have an edge over conventional treatments, which have a high relapse rate.
Cantab has also agreed to pay ImmunoLogic a further $11m if the two vaccines successfully complete Phase II clinical trials - the intermediate stage of drugs testing. In return, ImmunoLogic will transfer $6m in cash to Cantab to fund the development of the two compounds until the end of the year 2000.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments